mianserin has been researched along with Cognition Disorders in 9 studies
Mianserin: A tetracyclic compound with antidepressant effects. It may cause drowsiness and hematological problems. Its mechanism of therapeutic action is not well understood, although it apparently blocks alpha-adrenergic, histamine H1, and some types of serotonin receptors.
mianserin : A dibenzoazepine (specifically 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine) methyl-substituted on N-2. Closely related to (and now mostly superseded by) the tetracyclic antidepressant mirtazapinean, it is an atypical antidepressant used in the treatment of depression throughout Europe and elsewhere.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We aimed to evaluate predictors and mediators of enhancing effect of adjunctive mirtazapine on cognition in schizophrenia." | 9.17 | Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation. ( Burkin, M; Chukhin, E; Joffe, G; Joffe, M; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2013) |
| "This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia." | 9.15 | Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. ( Cho, SJ; Choi, TK; Kim, B; Kim, YW; Lee, JE; Lee, KS; Lee, SH; Suh, S; Yook, K; Yook, KH, 2011) |
| " In a double-blind placebo-controlled study we examined the effect of add-on mianserin (15 mg/day), an agent with marked 5-HT2A antagonism, on cognitive functioning in 30 chronic hospitalized DSM-IV schizophrenia patients stabilized on typical antipsychotics." | 9.10 | Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. ( Fuchs, C; Gonopolsky, I; Koren, D; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R, 2003) |
| "We aimed to evaluate predictors and mediators of enhancing effect of adjunctive mirtazapine on cognition in schizophrenia." | 5.17 | Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation. ( Burkin, M; Chukhin, E; Joffe, G; Joffe, M; Stenberg, JH; Terevnikov, V; Tiihonen, J, 2013) |
| "This preliminary study aimed to determine if adding mirtazapine to risperidone might improve negative and cognitive symptoms in schizophrenia." | 5.15 | Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial. ( Cho, SJ; Choi, TK; Kim, B; Kim, YW; Lee, JE; Lee, KS; Lee, SH; Suh, S; Yook, K; Yook, KH, 2011) |
| " In a double-blind placebo-controlled study we examined the effect of add-on mianserin (15 mg/day), an agent with marked 5-HT2A antagonism, on cognitive functioning in 30 chronic hospitalized DSM-IV schizophrenia patients stabilized on typical antipsychotics." | 5.10 | Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study. ( Fuchs, C; Gonopolsky, I; Koren, D; Poyurovsky, M; Schneidman, M; Weizman, A; Weizman, R, 2003) |
| "Mirtazapine adjunction was well tolerated and induced a significant improvement in cognitive performance, as measured by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS; Randolph, 1998) total score and by the subscales for immediate and delayed memory (p<." | 2.73 | Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine. ( Biondi, M; Delle Chiaie, R; Fiorentini, S; Salviati, M, 2007) |
| "Treatment with mirtazapine 30 mg orally daily and mefloquine hydrochloride 250 mg orally for three days, then 250 mg weekly, was initiated." | 1.38 | Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus. ( Jett, RA; Moenster, RP, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 5 (55.56) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loyaga-Rendon, RY | 1 |
| Taylor, DO | 1 |
| Koval, CE | 1 |
| Messer, T | 1 |
| Cho, SJ | 1 |
| Yook, K | 1 |
| Kim, B | 1 |
| Choi, TK | 1 |
| Lee, KS | 1 |
| Kim, YW | 1 |
| Lee, JE | 1 |
| Suh, S | 1 |
| Yook, KH | 1 |
| Lee, SH | 1 |
| Moenster, RP | 1 |
| Jett, RA | 1 |
| Stenberg, JH | 1 |
| Terevnikov, V | 1 |
| Joffe, M | 1 |
| Tiihonen, J | 1 |
| Chukhin, E | 1 |
| Burkin, M | 1 |
| Joffe, G | 1 |
| Poyurovsky, M | 1 |
| Koren, D | 1 |
| Gonopolsky, I | 1 |
| Schneidman, M | 1 |
| Fuchs, C | 1 |
| Weizman, A | 1 |
| Weizman, R | 1 |
| Schillerstrom, JE | 1 |
| Seaman, JS | 1 |
| Delle Chiaie, R | 1 |
| Salviati, M | 1 |
| Fiorentini, S | 1 |
| Biondi, M | 1 |
| Thompson, PJ | 1 |
| Trimble, MR | 1 |
4 trials available for mianserin and Cognition Disorders
| Article | Year |
|---|---|
Mirtazapine augmentation enhances cognitive and reduces negative symptoms in schizophrenia patients treated with risperidone: a randomized controlled trial.
Topics: Adult; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Cognition Disorders; Double-Blind Met | 2011 |
Predictors and mediators of add-on mirtazapine-induced cognitive enhancement in schizophrenia--a path model investigation.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adult; Antipsychotic Agents; Cognition; Cognition Disorders | 2013 |
Effect of the 5-HT2 antagonist mianserin on cognitive dysfunction in chronic schizophrenia patients: an add-on, double-blind placebo-controlled study.
Topics: Adult; Analysis of Variance; Chi-Square Distribution; Chronic Disease; Cognition Disorders; Double-B | 2003 |
Add-on mirtazapine enhances effects on cognition in schizophrenic patients under stabilized treatment with clozapine.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adult; Antipsychotic Agents; Brief Psychiatric R | 2007 |
5 other studies available for mianserin and Cognition Disorders
| Article | Year |
|---|---|
Progressive multifocal leukoencephalopathy in a heart transplant recipient following rituximab therapy for antibody-mediated rejection.
Topics: Antibodies, Monoclonal, Murine-Derived; Cognition Disorders; Fatal Outcome; Graft Rejection; Heart F | 2013 |
[Cognitive dysfunction in major depression].
Topics: Attention; Cognition Disorders; Depressive Disorder, Major; Drug Therapy, Combination; Executive Fun | 2015 |
Mirtazapine and mefloquine therapy for progressive multifocal leukoencephalopathy in a patient infected with human immunodeficiency virus.
Topics: Cognition Disorders; Histamine H1 Antagonists; HIV Infections; Humans; JC Virus; Leukoencephalopathy | 2012 |
Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient.
Topics: Aged; Antidepressive Agents, Tricyclic; Benzhydryl Compounds; Cachexia; Central Nervous System Stimu | 2002 |
Non-MAOI antidepressant drugs and cognitive functions: a review.
Topics: Amitriptyline; Antidepressive Agents; Cognition; Cognition Disorders; Depressive Disorder; Dose-Resp | 1982 |